GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » Cyclically Adjusted Revenue per Share

Enanta Pharmaceuticals (FRA:9EP) Cyclically Adjusted Revenue per Share : €6.70 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted revenue per share for the three months ended in Dec. 2024 was €0.763. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.70 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Enanta Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -4.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Enanta Pharmaceuticals was -6.10% per year. The lowest was -6.10% per year. And the median was -6.10% per year.

As of today (2025-05-07), Enanta Pharmaceuticals's current stock price is €4.40. Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was €6.70. Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.66.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enanta Pharmaceuticals was 11.00. The lowest was 0.68. And the median was 3.66.


Enanta Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 7.42 8.16 6.67 6.40

Enanta Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.75 6.83 6.65 6.40 6.70

Competitive Comparison of Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Enanta Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.763/133.1571*133.1571
=0.763

Current CPI (Dec. 2024) = 133.1571.

Enanta Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 2.751 99.621 3.677
201506 0.536 100.684 0.709
201509 0.664 100.392 0.881
201512 2.308 99.792 3.080
201603 0.617 100.470 0.818
201606 0.655 101.688 0.858
201609 0.595 101.861 0.778
201612 0.519 101.863 0.678
201703 0.440 102.862 0.570
201706 0.350 103.349 0.451
201709 3.113 104.136 3.981
201712 1.617 104.011 2.070
201803 1.734 105.290 2.193
201806 2.332 106.317 2.921
201809 2.733 106.507 3.417
201812 2.952 105.998 3.708
201903 1.663 107.251 2.065
201906 1.860 108.070 2.292
201909 2.232 108.329 2.744
201912 2.278 108.420 2.798
202003 1.255 108.902 1.535
202006 0.827 108.767 1.012
202009 1.000 109.815 1.213
202012 1.299 109.897 1.574
202103 0.838 111.754 0.998
202106 0.888 114.631 1.032
202109 0.991 115.734 1.140
202112 1.200 117.630 1.358
202203 0.827 121.301 0.908
202206 0.890 125.017 0.948
202209 0.989 125.227 1.052
202212 1.070 125.222 1.138
202303 0.790 127.348 0.826
202306 0.828 128.729 0.856
202309 0.842 129.860 0.863
202312 0.783 129.419 0.806
202403 0.741 131.776 0.749
202406 0.788 132.554 0.792
202409 0.621 133.029 0.622
202412 0.763 133.157 0.763

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Enanta Pharmaceuticals  (FRA:9EP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.40/6.70
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enanta Pharmaceuticals was 11.00. The lowest was 0.68. And the median was 3.66.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Enanta Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines